The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. This year’s metric has recorded a Price decrease of -37.06%. However, over the past six months, we’ve seen a stronger performance of -57.96%. The price of MBRX leaped by -39.20% over the last 30 days. And in the last five days, it has fallen by -50.92%.
In terms of market performance, Moleculin Biotech Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $10.35 on 03/11/24, while the lowest value was $0.40 on 02/12/25.
52-week price history of MBRX Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Moleculin Biotech Inc’s current trading price is -89.66% away from its 52-week high, while its distance from the 52-week low is 169.18%. The stock’s price range over this timeframe has been between $0.40 and $10.35. The shares of the Healthcare sector company recorded a trading volume of approximately 1.63 million for the day, which was comparatively lower than the average daily volume of 4.56 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Moleculin Biotech Inc (MBRX) has experienced a quarterly decline of -59.08% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.45M and boasts a workforce of 18 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.1015, with a change in price of -1.6800. Similarly, Moleculin Biotech Inc recorded 2,822,342 in trading volume during the last 100 days, posting a change of -61.09%.
MBRX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MBRX stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.05.
MBRX Stock Stochastic Average
Moleculin Biotech Inc’s raw stochastic average for the past 50 days is currently at 20.68%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 20.68%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 26.21% and 33.18%, respectively.
